Indications for AVELOX I.V.:
Susceptible infections including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), community acquired pneumonia, skin and skin structure, complicated intra-abdominal infections, plague. For ABS and ABECB: reserve for those who have no alternative treatment options.
≥18yrs: 400mg once daily. ABS: treat for 10 days. ABECB: treat for 5 days. Pneumonia: treat for 7–14 days. Skin and skin structure: treat for 7 days, if complicated: 7–21 days. Intra-abdominal: treat for 5–14 days. Plague: treat for 10–14 days; begin as soon as possible after suspected or confirmed exposure. IV formulation may be used if oral route not preferable; administer IV infusion over 60mins, may switch from IV to oral route when clinically indicated.
<18yrs: not established.
Serious adverse reactions including tendinitis/tendon rupture, peripheral neuropathy, central nervous system (CNS) effects. Exacerbation of myasthenia gravis.
AVELOX I.V. Warnings/Precautions:
Increased risk of disabling and potentially irreversible adverse reactions (including tendinitis/tendon rupture [esp. in patients >60yrs, or those with kidney, heart or lung transplants], peripheral neuropathy, or CNS/psychiatric effects); discontinue immediately if signs/symptoms occur. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. History of myasthenia gravis; avoid. History of QT prolongation, ventricular arrhythmias, proarrhythmic conditions (eg, bradycardia, acute myocardial ischemia), hypokalemia, or hypomagnesemia; avoid. Do not exceed recommended dose or infusion rate; may increase QT prolongation. Increased risk of aortic aneurysm and dissection (esp. in elderly); reserve use only if no alternatives in patients with history or risk of. Hepatic impairment. Monitor ECG in liver cirrhosis. Discontinue at 1st sign of a skin rash, jaundice, or any other hypersensitivity. Monitor blood glucose in diabetic patients; discontinue if hypoglycemia occurs. Maintain adequate hydration. Avoid excessive sun or UV light. Elderly. Pregnancy. Nursing mothers.
AVELOX I.V. Classification:
AVELOX I.V. Interactions:
Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, tricyclics). Oral forms: take at least 4hrs before or 8hrs after iron, zinc, magnesium, aluminum, sucralfate, didanosine (buffered forms). Increased risk of tendinitis/tendon rupture with corticosteroids. Concomitant antidiabetics may increase blood glucose disturbances. Increased seizure risk with concomitant NSAIDs. Monitor warfarin.
Nausea, diarrhea, dizziness, headache; tendinitis/tendon rupture, peripheral neuropathy, CNS effects, hypersensitivity reactions, phototoxicity (discontinue if occurs), QT prolongation, C. difficile-associated diarrhea, dysglycemia, aortic aneurysm/dissection.
Generic Drug Availability:
Tabs—30; Premixed IV soln (250mL)—1